tirzepatide for mash Eli Lilly's Shows Promise in Treating Fatty Liver Disease Nearly 62% achieve MASH resolution

In parallel with the above observations, the use of GSH in a combination treatment of MRAB especially with an antibiotic (at highest concentration, 5 MBC) resulted in the lowest recoverable CFU count (i.e., the lowest level of viability) (Figure 6)

Medication selection should consider health history, side effects, access, cost, insurance, nutrition, movement, monitoring, and long-term follow-up

The success of ePA with GLP-1s will be a bellwether for how well the healthcare system can handle specialty medications at scale

Perhaps the impact from GLP-1 will help to offset the slowed interest in discretionary within the current inflationary environment